- ►annals.org [PDF] EJ Whitney, RA Krasuski, BE Personius, JE … - Annals of internal medicine, 2005 - Am Coll Physicians Background: The high-density lipoprotein (HDL) cholesterol level is a strong
predictor of cardiovascular events in epidemio- logic studies. Until recently,
it has been less extensively studied as a therapeutic target. Objective: To ... Cited by 118 - Related articles - All 7 versions
- ►ahajournals.org AJ Taylor, LE Sullenberger, HJ Lee, JK Lee, … - Circulation, 2004 - Am Heart Assoc Methods and Results— This was a double-blind randomized placebo-controlled
study of once-daily extended-release niacin (1000 mg) added to background statin
therapy in 167 patients (mean age 67 years) with known coronary heart ... Cited by 521 - Related articles - All 6 versions
AJ Taylor, HJ Lee, LE Sullenberger - Current Medical Research and Opinion®, 2006 - informahealthcare.com Allen J. taylor, hyun J. lee and lance e. sullenberger ... Cardiology Service,
Walter Reed Army Medical Center, Washington, DC, USA ... Address for
correspondence: Allen J. Taylor, MD COL MC USA, Chief, Cardiology Service, ... Cited by 114 - Related articles - BL Direct - All 5 versions
PL Canner, CD Furberg, ML Terrin, ME … - The American journal of cardiology, 2005 - Elsevier The Coronary Drug Project, conducted during 1966 to 1974, was a randomized,
double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men
with previous myocardial infarction. 1 Among the 5 drug treatment regimens, ... Cited by 111 - Related articles - All 12 versions
T Rubic, M Trottmann, RL Lorenz - Biochemical pharmacology, 2004 - Elsevier Niacin, the first lipid lowering drug shown to improve survival after myocardial
infarction, decreases LDL and increases HDL cholesterol levels. These effects
cannot fully be explained by its suspected mechanism of action, inhibition ... Cited by 94 - Related articles - All 3 versions
ML Kashyap, ME McGovern, K Berra, JR … - The American journal of cardiology, 2002 - Elsevier Combination therapy is increasingly recommended for patients with multiple lipid
disorders, especially those at high risk for coronary events. We investigated
the long-term safety and effectiveness of a new drug formulation containing ... Cited by 227 - Related articles - BL Direct - All 8 versions
- ►bjmu.edu.cn [PDF] XQ Zhao, JS Morse, AA Dowdy, N Heise, D … - The American journal of cardiology, 2004 - Elsevier The high-density lipoprotein (HDL)-Atherosclerosis Treatment Study showed that
simvastatin plus niacin (mean daily dose 13 mg and 2.4 g, respectively) halt
angiographic atherosclerosis progression and reduce major clinical events ... Cited by 87 - Related articles - All 6 versions
- ►onlinejacc.org [PDF] RS Birjmohun, BA Hutten, JJP Kastelein, ESG … - Journal of the American College of Cardiology, 2005 - Elsevier Epidemiologic evidence has shown that HDL-C is inversely related to coronary
heart disease (CHD) risk. However, the evidence for reducing CHD risk by raising
HDL-C is thin, predominantly due to the paucity of effective and safe HDL- ... Cited by 191 - Related articles - All 14 versions
LA Carlson, G Rosenhamer - Acta Med Scand, 1988 - interscience.wiley.com Consecutive survivors of a myocardial infarction from the Southern Hospital,
below 70 years of age, were randomized into a Control group (n=276) and a
Treatment group (n=279). The latter was openly prescribed the combination ... Cited by 464 - Related articles - All 4 versions
- ►bmj.com T Meade, R Zuhrie, C Cook, J Cooper - British Medical Journal, 2002 - bmj.com Evidence from epidemiological research has shown strong associations between
high plasma fibrinogen concentrations and the onset and progression of arterial
disease at all three main sites that is, heart, brain, and lower ... Cited by 106 - Related articles - BL Direct - All 10 versions
